← boardnext 2027-06
BMEA
Biomea Fusion Inc.distress 6/10 · elevated risk$1.25-3%today-53% from 52w high
Oncology 3Metabolic / Obesity 2
Lead: Type 2 Diabetes · target Menin · est. market ~$70B (approx, global)
Revenue
pre-revenue
Liquidity
$46M
Runway
0.8 yrs
Shares 1y
+22%
Price & events
-12.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-0.8%
1W
+1.6%
1M
-33.1%
3M
-6.7%
6M
-32.4%
1Y
-77.6%
2Y
-90.6%
5Y
-93.3%
All
Overview
- Market Cap
- $90.38M
- Volume
- 25.66K
- 52 Week Range
- $0.96 – $2.67
- Total Shares
- 72.30M
- Float Shares
- 67.44M
- Short %
- 23.33%
- % Held by Insiders
- 7.17%
- % Held by Institutions
- 38.88%
- RVOL
- 0.03x
- Beta
- -0.33
Pipeline stages · 2 programs
icovamenib 100mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BMF-650
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | icovamenib 100mg | Type 2 Diabetes | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | icovamenib 100 mg | Type 2 Diabetes | — | recruiting |
| 2026-05 | Phase 1 | BMF-650 | Obesity | 80 | active not recruiting |
| 2026-04 | Phase 1 | BMF-500 | Acute Myeloid Leukemia | 35 | active not recruiting |
| 2026-01-14 | Phase 1 | Icovamenib, Icovamenib HPMC | Healthy Volunteer | 60 | completed |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-05-20 | Phase 2 | BMF-219 | Type 1 Diabetes Mellitus | 37 | terminated |
| 2025-02-13 | Phase 1 | BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | terminated |
| 2025-01-15 | Phase 1 | BMF-219 | Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors | 13 | terminated |
Catalyst news & presentations · 11
- 4Q 2026Guided 70%readoutPhase 2icovamenib · Phase II 26-week primary endpoint data from COVALENT-212 in patients not controlled on GLP-1-based therapies.SEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutPhase 2icovamenib · 52-week follow-up data from COVALENT-112.SEC 8-K
- second half of this yeartrial initiationsecondaryPhase 2icovamenib · Planned Phase 2 trial evaluating extended dosing and combination therapy in patients diagnosed within past 3 years.SEC 8-K
- Q2 2026readoutPhase 1BMF-650 · Phase I weight reduction data in obese healthy volunteers.SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)BMF-650 · IND submission for BMF-650SEC 8-K
- fourth quarter of 2025trial initiationsecondaryPhase 2icovamenib · Phase IIb trial initiationSEC 8-K
- second half 2025readoutPhase 2icovamenib · 52-week data from COVALENT-111SEC 8-K
- Q4 2024conferencedata presentationsecondaryAnnounce third development candidate, a GLP-1 receptor agonistSEC 8-K
- Q4 2024readoutPhase 2BMF-219 · Topline data readout of Phase 2a of COVALENT-112SEC 8-K
- 2024-09-26fda agreementBMF-219 · FDA lifted clinical hold on BMF-219 for type 2 and type 1 diabetes trialsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $7 (+447% upside) · 6 analysts
- 2026-05-05CitizensMarket Outperform
- 2026-04-28D. Boral CapitalBuy
- 2026-04-08D. Boral CapitalBuy
- 2026-03-27CitigroupBuy
- 2026-03-25D. Boral CapitalBuy
- 2026-01-13D. Boral CapitalBuy
Recent news
- 2026-07-14BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, - GuruFocus
- 2026-07-03Biomea Fusion Inc. (BMEA) Q1 2026 Earnings: Narrower-than-expected loss highlights cost management - Return On Equity - dars.gov.et
- 2026-06-28Price to earnings forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
- 2026-06-27Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
- 2026-06-26Biomea Fusion Inc Actuals & Estimates (NASDAQ:BMEA) - TradingView
- 2026-06-25BMEA Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-20Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-06-20Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.